Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen
As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.
as measured by RBD-binding IgG concentrations and SARS-CoV-2 …
fully human anti-PD-L1 IgG1 monoclonal antibody, in ovarian cancer patients,” said Dr. Briggs W. Morrison, Syndax’s Chief …
Behind the Science Features
Press Releases
11.19.2009
10.31.2008
06.21.2007
Media Resources
This information is intended for media professionals. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Clinical Trials
Our Careers